H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced a new product candidate LCP-Siro. The active ingredient in LCP-Siro is Sirolimus, an immunosuppressant for the prevention of organ rejection after transplantation and for the treatment of certain autoimmune diseases. The Company has also initiated a Phase I clinical trial for LCP-Siro in healthy volunteers. Data from the Phase I clinical trial is expected in 2008.
